VYVGART Drug Profile

Summary for Tradename: VYVGART

High Confidence Patents:	0
Applicants:	1
BLAs:	2
Recent Clinical Trials:	See clinical trials for VYVGART

Recent Clinical Trials for VYVGART

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Chafic Karam	Phase 2
argenx	Phase 2

See all VYVGART clinical trials

Pharmacology for VYVGART

Mechanism of Action	Neonatal Fc Receptor Blockers
Established Pharmacologic Class	Neonatal Fc Receptor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VYVGART Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VYVGART Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VYVGART Derived from Patent Text Search

No patents found based on company disclosures

VYVGART Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook

Last updated: September 7, 2026

VYVGART is argenx SE's lead commercial product and the main growth driver of its valuation. The efgartigimod franchise generated approximately $2.2 billion in 2024 net product sales, up from about $1.2 billion in 2023. Growth has come from rapid adoption in generalized myasthenia gravis (gMG), conversion from intravenous VYVGART to subcutaneous VYVGART Hytrulo, and the June 2024 U.S. approval for chronic inflammatory demyelinating polyneuropathy (CIDP). [1]

The principal commercial risks are concentration in one molecule, dependence on repeat dosing, competition from other neonatal Fc receptor (FcRn) blockers, payer control over biologic therapy, and long-term biosimilar or follow-on competition. The franchise has meaningful protection from formulation, manufacturing, regulatory exclusivity, and use patents, but its effective exclusivity period depends on the jurisdiction and the scope of the patent families rather than a single expiry date.

How large is the VYVGART market?

VYVGART addresses antibody-mediated autoimmune diseases by blocking FcRn recycling. This lowers circulating pathogenic immunoglobulin G (IgG) antibodies without broadly eliminating B cells or suppressing the entire immune system.

The initial market was gMG, a rare autoimmune neuromuscular disease affecting an estimated 60,000 to 80,000 people in the United States. The CIDP approval expanded the addressable population materially. CIDP is a chronic immune-mediated peripheral nerve disorder with a larger treatment population than gMG and established use of immunoglobulin replacement therapy.

Market driver	Effect on VYVGART
gMG approval	Established the initial commercial market in 2021
Subcutaneous VYVGART Hytrulo	Improved administration convenience and reduced infusion-center dependence
CIDP approval	Expanded the addressable population beyond gMG
FcRn mechanism	Creates a differentiated alternative to steroids, immunosuppressants, IVIg, and plasma exchange
Repeat dosing	Supports recurring revenue but increases payer and adherence sensitivity
Rare-disease infrastructure	Supports specialist prescribing and high treatment persistence

The commercial model is closer to chronic specialty therapy than to a one-time biologic intervention. Patients generally require repeated treatment cycles, making net sales depend on treated-patient growth, dosing frequency, persistence, reimbursement, and the mix between IV and subcutaneous products.

What are VYVGART sales and argenx's financial trajectory?

argenx reported a sharp acceleration in revenue after the U.S. launch. The company moved from pre-commercial development into a high-growth specialty pharmaceutical model within two years.

Fiscal year	Approximate argenx revenue or VYVGART product sales	Financial significance
2021	Initial commercial launch	U.S. VYVGART IV approval and launch
2022	Approximately $300 million company revenue	Early launch and international expansion
2023	Approximately $1.2 billion net product sales	Broad gMG uptake and growing global commercialization
2024	Approximately $2.2 billion net product sales	Continued gMG growth, VYVGART Hytrulo expansion, CIDP approval
2025 guidance	Approximately $2.7 billion to $3.0 billion in expected net product sales, according to company guidance	Further penetration and CIDP commercialization

The 2024 performance represented roughly 80% year-over-year growth from 2023. That growth rate is unlikely to remain constant as the U.S. gMG market matures, but the CIDP launch provides a second growth vector.

argenx has been investing heavily in commercial infrastructure, medical affairs, manufacturing capacity, and clinical development. The key financial question is whether gross-profit growth will outpace spending as the company commercializes additional indications. A successful scale-up would allow VYVGART revenue to support broader clinical development without materially increasing financing needs.

What drives VYVGART revenue?

The main revenue variables are:

1. New patient starts in gMG.
2. Conversion from IVIg or other maintenance therapy.
3. Treatment persistence and retreatment frequency.
4. Uptake of VYVGART Hytrulo over VYVGART IV.
5. CIDP diagnosis and reimbursement.
6. International launch timing.
7. Net price after rebates and government discounts.
8. Expansion into additional FcRn-sensitive autoimmune diseases.

The move to VYVGART Hytrulo is commercially important because subcutaneous delivery can be administered outside a hospital or infusion center, depending on local practice and label requirements. It also gives argenx a lifecycle-management product that can defend market share as competitors introduce competing FcRn therapies.

What is VYVGART's FDA regulatory status?

The FDA approved VYVGART IV in December 2021 for adults with anti-acetylcholine receptor antibody-positive gMG. The FDA approved VYVGART Hytrulo in June 2023 for adults with gMG who are anti-AChR antibody positive.

In June 2024, the FDA approved VYVGART Hytrulo for adults with CIDP. The CIDP approval was based on the ADHERE study, which evaluated time to adjusted INCAT deterioration and demonstrated a lower risk of disease worsening for treated patients compared with placebo. [2]

Product	Active ingredient	Route	U.S. approval	Primary indication
VYVGART	Efgartigimod alfa	Intravenous infusion	December 2021	Anti-AChR antibody-positive gMG
VYVGART Hytrulo	Efgartigimod alfa plus recombinant human hyaluronidase	Subcutaneous injection	June 2023	Anti-AChR antibody-positive gMG
VYVGART Hytrulo	Efgartigimod alfa plus recombinant human hyaluronidase	Subcutaneous injection	June 2024	CIDP

The FDA classifies VYVGART as a biologic. Its U.S. regulatory framework is therefore governed primarily by the Public Health Service Act and the Biologics Price Competition and Innovation Act (BPCIA), rather than the small-molecule Hatch-Waxman pathway.

What patents protect VYVGART?

VYVGART is protected by a layered intellectual-property estate covering the engineered Fc fragment, FcRn binding and antagonism, pharmaceutical formulations, subcutaneous delivery, hyaluronidase combinations, manufacturing processes, and therapeutic uses.

The relevant protection is distributed across U.S. and foreign patent families. Patent terms may differ by family because of priority dates, patent-term adjustment, patent-term extension, terminal disclaimers, and prosecution history. A single public expiry date should not be treated as the end of all VYVGART protection.

What formulations are protected by VYVGART patents?

The subcutaneous product adds protection beyond the original intravenous product. The combination of efgartigimod alfa with recombinant human hyaluronidase supports claims directed to:

• Subcutaneous administration.
• Reduced-volume delivery.
• Co-formulation or co-administration.
• Dosing schedules for chronic autoimmune disease.
• Stability and concentration characteristics.
• Manufacturing and quality-control processes.

This distinction matters commercially. Even if a future competitor reaches the market with an IV FcRn blocker, VYVGART Hytrulo may retain a delivery and convenience advantage. Conversely, a competing subcutaneous FcRn product could pressure both price and persistence.

When does VYVGART lose exclusivity?

VYVGART does not have one definitive U.S. loss-of-exclusivity date comparable to a conventional small molecule listed in the Orange Book. The effective exclusivity timeline includes:

• FDA biologic reference-product exclusivity.
• Patent protection for efgartigimod alfa.
• Patent protection for VYVGART Hytrulo.
• Method-of-use patents.
• Manufacturing and formulation patents.
• Regulatory exclusivity in individual foreign markets.

The FDA reference-product exclusivity period for a new biologic is generally four years against submission of a biosimilar application and 12 years against approval of the biosimilar under the BPCIA. VYVGART's first U.S. approval occurred in December 2021, placing the four-year application bar in December 2025 and the 12-year reference-product exclusivity period in December 2033, subject to statutory interpretation and regulatory treatment. [3]

These dates do not establish the earliest possible commercial biosimilar entry. Patent litigation, settlements, pediatric extensions, and product-specific patent claims can move practical entry later.

Does VYVGART have an Orange Book listing?

No. VYVGART is a biologic, so it is not listed in the FDA Orange Book as a conventional New Drug Application product. Biologic reference products and biosimilar relationships are tracked through the FDA Purple Book. Patent disputes generally arise under the BPCIA patent-exchange and litigation framework rather than through a standard Paragraph IV certification.

The absence of an Orange Book listing does not mean the product lacks patent protection. It means that the legal pathway for challenging those patents is different.

Are there Paragraph IV challenges or biosimilar risks?

A conventional Paragraph IV challenge does not apply to VYVGART in the same way it applies to a small-molecule drug. A biosimilar applicant could instead provide a patent notice under the BPCIA and challenge patents through federal litigation.

Through the end of 2024, there was no FDA-approved efgartigimod biosimilar and no publicly reported major BPCIA litigation involving an approved VYVGART biosimilar. The long-term threat remains material because FcRn antibodies and fragments are biologic products with potentially attractive commercial economics.

Biosimilar risk is likely to develop in stages:

1. Patent and manufacturing feasibility work by potential entrants.
2. BPCIA information exchange and patent selection.
3. Litigation over composition, formulation, administration, and use claims.
4. Settlement negotiations that could permit a licensed or delayed entry.
5. Commercial competition after approval.

Manufacturing is a meaningful barrier. A biosimilar applicant must demonstrate analytical similarity, process control, comparability, immunogenicity management, and reliable supply. For VYVGART Hytrulo, the dual-product configuration adds complexity because the applicant may need to reproduce both efgartigimod and the hyaluronidase delivery system.

Which companies challenge VYVGART commercially?

The most direct competitor is UCB's RYSTIGGO, or rozanolixizumab, an FcRn antagonist approved in the United States in 2023 for adults with gMG who are anti-AChR or anti-muscle-specific kinase antibody positive. RYSTIGGO is administered subcutaneously and competes directly with VYVGART Hytrulo on mechanism, specialist adoption, dosing convenience, and payer positioning. [4]

Product	Company	Mechanism	Key U.S. market
VYVGART	argenx	FcRn antagonist	gMG
VYVGART Hytrulo	argenx	FcRn antagonist plus hyaluronidase	gMG and CIDP
RYSTIGGO	UCB	FcRn antagonist	gMG
ULTOMIRIS	AstraZeneca	C5 complement inhibition	gMG and other complement-mediated diseases
SOLIRIS	AstraZeneca	C5 complement inhibition	gMG and other complement-mediated diseases
IVIg products	Multiple manufacturers	Immunoglobulin replacement	gMG and CIDP
Plasma exchange	Multiple providers	Antibody removal	Severe or refractory disease

The competitive market is not limited to FcRn blockers. IVIg, corticosteroids, nonsteroidal immunosuppressants, complement inhibitors, plasma exchange, and emerging B-cell therapies all compete for treatment decisions and payer budgets.

What licensing deals affect VYVGART?

argenx entered a regional collaboration with Zai Lab covering development and commercialization of efgartigimod in Greater China. Publicly reported terms included an upfront payment of approximately $75 million and potential milestone payments of up to approximately $1.5 billion, plus royalties and other commercial economics. [5]

The agreement reduces argenx's need to build a full commercial organization in Greater China while giving Zai Lab an opportunity to commercialize a differentiated autoimmune biologic. It also creates dependence on a regional partner for regulatory execution, reimbursement, market access, and launch performance.

argenx has retained a direct commercial role in major markets, including the United States and key European territories. The resulting model combines high-margin direct sales with selected regional partnerships.

What litigation and settlement risks affect VYVGART?

No major publicly reported VYVGART patent settlement or biosimilar launch had materially altered the U.S. market through the end of 2024. The most relevant future disputes are likely to concern:

• Efgartigimod composition claims.
• FcRn-binding and antagonist claims.
• VYVGART Hytrulo subcutaneous administration.
• Hyaluronidase combination claims.
• Dosing regimens for gMG and CIDP.
• Manufacturing and formulation claims.
• Potential off-label or label-supported use patents.

A settlement with a biosimilar applicant could preserve branded revenue while establishing an agreed future entry date. A court invalidity decision involving core composition claims would have a greater commercial effect than a narrow dosing-patent loss.

How strong is the VYVGART patent estate?

The estate is commercially strong because protection is layered across product identity, delivery, formulation, use, and manufacturing. Its strongest assets are likely the claims that are difficult to design around while preserving the same clinical and delivery profile.

The estate is less secure if protection depends mainly on narrow dosing or indication claims. Competitors may pursue different FcRn molecules, different subcutaneous delivery systems, or alternative dosing schedules. The practical strength of the estate therefore depends on claim breadth, patent validity, freedom-to-operate analysis, and the ability to enforce patents against a biosimilar or competing biologic.

What is the outlook for VYVGART revenue?

The base commercial outlook remains favorable through the second half of the decade. gMG provides an established revenue base, while CIDP offers additional patient volume and recurring treatment demand. VYVGART Hytrulo can improve retention and reduce administration friction.

The primary upside factors are:

• Rapid CIDP diagnosis and reimbursement.
• Broader use earlier in treatment.
• Successful conversion from IVIg.
• Expansion into additional autoimmune indications.
• International uptake.
• Continued subcutaneous market share.

The primary downside factors are:

• Slower CIDP adoption.
• Reimbursement restrictions.
• FcRn class competition.
• Lower-than-expected treatment persistence.
• Manufacturing interruptions.
• Pricing pressure.
• Earlier-than-expected biosimilar entry.

VYVGART revenue is becoming large enough that future argenx valuation depends less on clinical proof of concept and more on durable commercial execution, lifecycle management, and portfolio diversification.

Key Takeaways

• VYVGART generated approximately $2.2 billion in 2024 net product sales, compared with approximately $1.2 billion in 2023.
• The June 2024 CIDP approval materially expanded the franchise beyond gMG.
• VYVGART Hytrulo is the key lifecycle product because it offers subcutaneous delivery and supports chronic outpatient treatment.
• VYVGART is a biologic and does not follow the conventional Orange Book or Paragraph IV pathway.
• The U.S. biologic reference-product exclusivity period generally extends to 2033 based on the December 2021 approval date, but patent protection may run on different timelines.
• RYSTIGGO is the most direct commercial competitor.
• No approved efgartigimod biosimilar or major public BPCIA litigation had materially changed the market through the end of 2024.
• The principal financial risk is dependence on one molecule and one therapeutic class despite rapid revenue growth.

FAQs

Is VYVGART a blockbuster drug?

Yes. VYVGART exceeded the conventional $1 billion annual-sales threshold in 2023 and generated approximately $2.2 billion in 2024 net product sales.

Is VYVGART approved for CIDP?

Yes. The FDA approved VYVGART Hytrulo for adults with CIDP in June 2024.

Is VYVGART the same as VYVGART Hytrulo?

No. VYVGART is the intravenous formulation. VYVGART Hytrulo combines efgartigimod alfa with recombinant human hyaluronidase for subcutaneous administration.

Can a generic company make VYVGART?

A conventional generic cannot be substituted for VYVGART under the small-molecule pathway. A competitor would need to pursue a biosimilar or another biologic product, subject to the BPCIA, FDA approval requirements, and patent disputes.

What is the largest threat to VYVGART sales?

The largest near-term threat is direct competition from other FcRn blockers, particularly RYSTIGGO, combined with payer controls and pricing pressure. Longer term, biosimilar entry and alternative autoimmune therapies could reduce market share.

References

1. argenx SE. (2025). Annual report 2024 and fourth-quarter 2024 financial results.
2. U.S. Food and Drug Administration. (2024, June 21). FDA approves treatment for chronic inflammatory demyelinating polyneuropathy.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
4. U.S. Food and Drug Administration. (2023, June 26). FDA approves new treatment for adults with generalized myasthenia gravis.
5. Zai Lab Limited. (2021). Zai Lab and argenx announce exclusive collaboration and license agreement for efgartigimod in Greater China.